trial

Safety, Blood Levels and Effects of AUT00206

NCTId NCT02589262
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment —
Sponsored by Autifony Therapeutics Limited
Primary completion 2016-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
—
Study type
Interventional
Allocation
—
Model
—
Masking
—
Start
2015-09
Primary completion
2016-07
Eligibility
MALE · 18 Years · 45 Years

Interventions & indications

Drugs
AUT00206

Sponsors

Autifony Therapeutics LimitedLead Sponsor

Sites

1 total
London, United Kingdom

Facts & assertions

3 sourced
Phase
PHASE1
Primary Completion Date
2016-07
Status
COMPLETED
relationships
The graph out of here
drug
AUT00206
drug
lead_sponsor
Autifony Therapeutics Limited
company
indication
Schizophrenia
indication
Schizophrenia
indication